| P2093 | author name string | Jun Wang | |
| | Xiao Chen | |
| | Jiacan Su | |
| | Xin Zhi | |
| P2860 | cites work | The many ways of osteoclast activation. | Q50988892 |
| | Coupling of bone resorption and formation by RANKL reverse signalling | Q59051790 |
| | Wnt/beta-catenin signaling induces the expression and activity of betaTrCP ubiquitin ligase receptor | Q73958568 |
| | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | Skeletal remodeling in health and disease | Q28235713 |
| | Matrix-embedded cells control osteoclast formation | Q28247746 |
| | Denosumab for prevention of fractures in postmenopausal women with osteoporosis | Q28254528 |
| | WNT signaling in bone homeostasis and disease: from human mutations to treatments | Q28285090 |
| | Denosumab in postmenopausal women with low bone mineral density | Q28298728 |
| | OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 |
| | Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial | Q30978614 |
| | The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension | Q34396612 |
| | PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis | Q34474147 |
| | Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension | Q36153179 |
| | Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells | Q36223256 |
| | SIRT6 safeguards human mesenchymal stem cells from oxidative stress by coactivating NRF2. | Q36559986 |
| | Beta-catenin-NF-κB interactions in murine hepatocytes: a complex to die for. | Q36592380 |
| | RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 |
| | TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation | Q37307155 |
| | Inhibition of osteoblastic bone formation by nuclear factor-kappaB. | Q37401772 |
| | Regulation of Osteoblast Migration Involving Receptor Activator of Nuclear Factor-kappa B (RANK) Signaling. | Q38884628 |
| | Murine Rankl-/- Mesenchymal Stromal Cells Display an Osteogenic Differentiation Defect Improved by a RANKL-Expressing Lentiviral Vector | Q39014215 |
| | RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. | Q40343811 |
| | IKKβ is a β-catenin kinase that regulates mesenchymal stem cell differentiation | Q49788187 |
| | STAC2 negatively regulates osteoclast formation by targeting the RANK signaling complex | Q49950374 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | mesenchymal stem cell | Q1922379 |
| P304 | page(s) | 34 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | Bone research | Q26842189 |
| P1476 | title | RANKL signaling in bone marrow mesenchymal stem cells negatively regulates osteoblastic bone formation | |
| P478 | volume | 6 | |